MA28142A1 - Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif - Google Patents
Medicament contenant un acide (2r)-2-propyloctanoique comme principe actifInfo
- Publication number
- MA28142A1 MA28142A1 MA28991A MA28991A MA28142A1 MA 28142 A1 MA28142 A1 MA 28142A1 MA 28991 A MA28991 A MA 28991A MA 28991 A MA28991 A MA 28991A MA 28142 A1 MA28142 A1 MA 28142A1
- Authority
- MA
- Morocco
- Prior art keywords
- propyloctanoic acid
- active ingredient
- drug
- drug containing
- present
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 3
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229910052728 basic metal Inorganic materials 0.000 abstract 1
- -1 basic metal ion Chemical class 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229910000000 metal hydroxide Inorganic materials 0.000 abstract 1
- 150000004692 metal hydroxides Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Details Of Rigid Or Semi-Rigid Containers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention porte sur un médicament qui est utile contre les maladies neurodégénératives, qui comprend 1 à 5 équivalents environ de l'ion de métal basique basé sur 1 équivalent de l'acide (2R)-2-propyloctanoïque ou son sel, qui est pourvu d'un sel de métal d'un acide faible ou un hydroxyde de métal, et comprend facultativement un additif de plus. Le médicament de la présente invention est un médicament qui possède un pH convenable pour l'administration par voie intraveineuse. Il est résistant au changement de pH et n'est pas pulvérisé quand il est dissout dans une infusion ou une injection, et les propriétés similaires peuvent être préparées par l'emploi d'un liquide de dissolution et/ou d'un liquide de dilution.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003345124 | 2003-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28142A1 true MA28142A1 (fr) | 2006-09-01 |
Family
ID=34419441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28991A MA28142A1 (fr) | 2003-10-03 | 2006-05-02 | Medicament contenant un acide (2r)-2-propyloctanoique comme principe actif |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8053599B2 (fr) |
| EP (1) | EP1669065B1 (fr) |
| JP (1) | JP4715515B2 (fr) |
| KR (1) | KR101144553B1 (fr) |
| CN (1) | CN1889942B (fr) |
| AU (1) | AU2004277826B2 (fr) |
| BR (1) | BRPI0415001A (fr) |
| CA (1) | CA2540670A1 (fr) |
| EC (1) | ECSP066477A (fr) |
| ES (1) | ES2390055T3 (fr) |
| IL (1) | IL174655A0 (fr) |
| IS (1) | IS8430A (fr) |
| MA (1) | MA28142A1 (fr) |
| MX (1) | MXPA06003533A (fr) |
| NO (1) | NO20061460L (fr) |
| NZ (1) | NZ546231A (fr) |
| RU (1) | RU2388467C2 (fr) |
| SG (1) | SG146687A1 (fr) |
| TW (1) | TW200519080A (fr) |
| WO (1) | WO2005032536A1 (fr) |
| ZA (1) | ZA200602690B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200613009A (en) * | 2004-06-11 | 2006-05-01 | Ono Pharmaceutical Co | Capsule having chewing stability |
| MY147790A (en) * | 2005-04-28 | 2013-01-31 | Takeda Pharmaceutical | Stable emulsion composition |
| JP5541845B2 (ja) * | 2008-03-28 | 2014-07-09 | Ｊｃｒファーマ株式会社 | アトピー性皮膚炎治療剤 |
| RU2561057C2 (ru) * | 2008-11-04 | 2015-08-20 | Аска Фармасьютикал Ко., Лтд. | Водная композиция, содержащая фолликулостимулирующий гормон |
| NZ590802A (en) | 2008-11-20 | 2013-05-31 | Techno Guard Co Ltd | Formulation comprising a pyrazolone derivative and an amphiphilic solubilising agent |
| JP5759804B2 (ja) * | 2011-06-27 | 2015-08-05 | 富士フイルム株式会社 | 容器詰製剤 |
| JP2018052861A (ja) * | 2016-09-29 | 2018-04-05 | ノーベルファーマ株式会社 | ホスフェニトインナトリウム注射剤 |
| WO2020128928A1 (fr) * | 2018-12-19 | 2020-06-25 | Jafari Javid Mihan | Formulation pour le traitement de troubles neurodégénératifs ainsi que de démyélinisation et neuropathiques et sa méthode de préparation |
| CN110441421B (zh) * | 2019-08-02 | 2022-09-09 | 聊城高新生物技术有限公司 | 一种高效液相色谱法测定恩他卡朋片溶出度的方法 |
| CN112180095B (zh) * | 2020-06-04 | 2023-10-13 | 三诺生物传感股份有限公司 | 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法 |
| IT202000015895A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | L’impiego di acido arundico nella terapia della sclerosi multipla |
| AU2022280595B2 (en) | 2021-05-26 | 2024-11-14 | Daewoong Pharmaceutical Co., Ltd. | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| CN113341019A (zh) * | 2021-06-09 | 2021-09-03 | 江西省药品检验检测研究院 | 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0632008B1 (fr) * | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Dérivés de l'acide pentanoique |
| JPH0782146A (ja) * | 1993-07-23 | 1995-03-28 | Sagami Chem Res Center | 抗痴呆薬 |
| JPH07285911A (ja) | 1994-04-20 | 1995-10-31 | New Japan Chem Co Ltd | 脂肪族モノカルボン酸組成物 |
| JPH0853351A (ja) | 1994-08-11 | 1996-02-27 | Sagami Chem Res Center | 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤 |
| JP3032447B2 (ja) | 1995-04-24 | 2000-04-17 | 小野薬品工業株式会社 | 光学活性な２−プロピルオクタン酸の製造方法 |
| JP3084345B2 (ja) | 1995-04-26 | 2000-09-04 | 小野薬品工業株式会社 | 光学活性な２−プロピルオクタン酸の製造方法 |
| JPH10298072A (ja) | 1997-04-17 | 1998-11-10 | Panacea Biotec Ltd | 非ステロイド性抗炎症剤の遷移金属錯体 |
| US6043223A (en) * | 1997-11-12 | 2000-03-28 | The Regents Of The University Of California | Enhanced opening of abnormal brain tissue capillaries |
| TWI268921B (en) * | 1999-02-18 | 2006-12-21 | Ono Pharmaceutical Co | A process for preparing (2R)-2-propyloctanoic acid |
| US6552082B2 (en) * | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
| JP4706950B2 (ja) * | 2000-07-18 | 2011-06-22 | 小野薬品工業株式会社 | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
| KR100759771B1 (ko) * | 2000-07-18 | 2007-10-04 | 오노 야꾸힝 고교 가부시키가이샤 | 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제 |
| CA2453478A1 (fr) | 2001-07-18 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Agent pour le traitement des maladies ischemiques cerebrales |
-
2004
- 2004-10-01 WO PCT/JP2004/014892 patent/WO2005032536A1/fr not_active Ceased
- 2004-10-01 JP JP2005514507A patent/JP4715515B2/ja not_active Expired - Fee Related
- 2004-10-01 MX MXPA06003533A patent/MXPA06003533A/es not_active Application Discontinuation
- 2004-10-01 NZ NZ546231A patent/NZ546231A/en unknown
- 2004-10-01 CA CA002540670A patent/CA2540670A1/fr not_active Abandoned
- 2004-10-01 TW TW093129802A patent/TW200519080A/zh unknown
- 2004-10-01 ES ES04792177T patent/ES2390055T3/es not_active Expired - Lifetime
- 2004-10-01 EP EP04792177A patent/EP1669065B1/fr not_active Expired - Lifetime
- 2004-10-01 BR BRPI0415001-5A patent/BRPI0415001A/pt not_active Application Discontinuation
- 2004-10-01 US US10/574,477 patent/US8053599B2/en not_active Expired - Fee Related
- 2004-10-01 KR KR1020067008535A patent/KR101144553B1/ko not_active Expired - Fee Related
- 2004-10-01 SG SG200807282-9A patent/SG146687A1/en unknown
- 2004-10-01 AU AU2004277826A patent/AU2004277826B2/en not_active Ceased
- 2004-10-01 CN CN2004800361288A patent/CN1889942B/zh not_active Expired - Fee Related
- 2004-10-01 RU RU2006114835/15A patent/RU2388467C2/ru not_active IP Right Cessation
-
2006
- 2006-03-30 IL IL174655A patent/IL174655A0/en unknown
- 2006-03-31 NO NO20061460A patent/NO20061460L/no not_active Application Discontinuation
- 2006-03-31 ZA ZA200602690A patent/ZA200602690B/en unknown
- 2006-04-03 EC EC2006006477A patent/ECSP066477A/es unknown
- 2006-04-26 IS IS8430A patent/IS8430A/is unknown
- 2006-05-02 MA MA28991A patent/MA28142A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005032536A1 (fr) | 2005-04-14 |
| CA2540670A1 (fr) | 2005-04-14 |
| AU2004277826A1 (en) | 2005-04-14 |
| KR20060099525A (ko) | 2006-09-19 |
| NZ546231A (en) | 2009-09-25 |
| TW200519080A (en) | 2005-06-16 |
| IS8430A (is) | 2006-04-26 |
| EP1669065A4 (fr) | 2009-12-16 |
| CN1889942A (zh) | 2007-01-03 |
| US20070105956A1 (en) | 2007-05-10 |
| IL174655A0 (en) | 2006-08-20 |
| JPWO2005032536A1 (ja) | 2006-12-14 |
| SG146687A1 (en) | 2008-10-30 |
| CN1889942B (zh) | 2010-12-15 |
| EP1669065A1 (fr) | 2006-06-14 |
| ZA200602690B (en) | 2007-07-25 |
| ECSP066477A (es) | 2007-03-29 |
| NO20061460L (no) | 2006-07-03 |
| RU2006114835A (ru) | 2007-11-20 |
| AU2004277826B2 (en) | 2010-05-27 |
| JP4715515B2 (ja) | 2011-07-06 |
| EP1669065B1 (fr) | 2012-07-18 |
| ES2390055T3 (es) | 2012-11-06 |
| US8053599B2 (en) | 2011-11-08 |
| KR101144553B1 (ko) | 2012-05-11 |
| RU2388467C2 (ru) | 2010-05-10 |
| BRPI0415001A (pt) | 2006-11-07 |
| MXPA06003533A (es) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105283170B (zh) | 包含肾上腺素和柠檬酸的可注射的药物组合物 | |
| DE3872029T2 (de) | Rektal absorbierbare form von l-dopa. | |
| JPH07116029B2 (ja) | トラニラスト水溶液製剤 | |
| WO2009098716A2 (fr) | Compositions pharmaceutiques aqueuses stables | |
| US20110118199A1 (en) | Use of cns penetrating anticancer compounds for the treatment of protozoal diseases | |
| JP2020073606A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
| JP6508655B2 (ja) | メガリン拮抗剤 | |
| SG146687A1 (en) | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | |
| JPWO2006049250A1 (ja) | 眼内移行性促進水性点眼剤 | |
| JP5258329B2 (ja) | プラノプロフェン含有水性医薬組成物 | |
| AU7308998A (en) | A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs | |
| MA28143A1 (fr) | Preparation de transfusion contenant un acide (2r)-2-propyloctanoique comme ingredient actif | |
| AR033312A1 (es) | Composicion que consta de un agonista alfa-2 adrenergico y un acido graso | |
| RU2666961C2 (ru) | Эмульсионная композиция дифлюпредната, содержащая антимикробный металл | |
| EP0599943A1 (fr) | Complexe antagoniste de recepteur de leucotrienes-antihistamine | |
| KR20190141871A (ko) | 안정성을 개선한 이부프로펜 약학 조성물 | |
| EP0920320A2 (fr) | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol | |
| US20140350097A1 (en) | Treatment of hypotension associated with hemodialysis | |
| JPH08198746A (ja) | 可溶化点眼剤 | |
| KR20060061351A (ko) | 글리시리진 고농도 제제 | |
| EP0029790B1 (fr) | Nouveau médicament à base d'aspirine et d'heptaminol | |
| JP4508628B2 (ja) | 眼科用組成物 | |
| KR930001302B1 (ko) | 시플로플록사신의 주사용 조성물 및 그 제조방법 | |
| CN102497854A (zh) | 含有作为防腐剂的丙酸衍生物的眼用液体药物组合物 | |
| JP2004123632A (ja) | 消炎鎮痛外用剤 |